Wei-Qi Wei

Researchers at Vanderbilt University Medical Center have developed a new method for identifying drugs for the repurposing trials that can lead to new indications for drugs already in use.

Vanderbilt University Medical Center has been awarded a five-year, $6 million grant from the National Institutes of Health to serve as a center of excellence for Maternal and Pediatric Precision in Therapeutics.

At the start of the COVID-19 pandemic, public health authorities first had to identify and draw attention to common signs and symptoms of the disease.

Wei-Qi Wei, MD, PhD, assistant professor of Biomedical Informatics and scientific director of the Precision Phenotyping Core at the Center for Precision Medicine, has been awarded a four-year, $1.7 million grant from the National Institutes of Health (grant GM139891) to continue

This spring in the U.S., there were widespread delays in elective health care procedures and screenings. Hospitals, in observance of federal guidelines, were, for a time, conserving beds and protective equipment in preparation for a surge in COVID-19 admissions. And, perhaps on a more prolonged basis, patients in many areas of the country stayed away due to anxiety over catching COVID-19 from other patients or their health care team.

Electronic health records (EHR) are increasingly a resource for biomedical discovery, and automated searches for records that reflect a phenotype of interest, typically a disease, are a common starting point.